BioPharma Dive April 3, 2025
BioPharma Dive data show the median biotech venture round remained near $100 million, continuing a trend toward larger financings that began in 2024.
Biotechnology company funding rounds remain larger than they were in 2022 and 2023, in a sign venture firms continue to favor bigger bets rather than parceling their money into smaller, but more numerous, financings.
The median funding round involving one of the roughly two dozen venture firms tracked by BioPharma Dive was worth $93 million during the first three months of 2025, according to BioPharma Dive data. That’s roughly equal to the median for the same period last year, but higher than any other quarter in the two years previous.
Median figures for financings in the second,...
Today's Sponsors
Today's Sponsor